

Tumour Bank Core Unit

Summary

The Tumour Bank Unit provides samples and related ethical documentation support to CNIO Groups and Units mainly through the Spanish National Tumour Bank Network. This network was created in September 2000 and currently incorporates 25 institutions. These associated biobanks are autonomous: tissue samples belong to – and reside within – the respective hospitals. We maintain collaborations with other biobanks as a part of the *Red Temática de Biobancos Hospitalarios-ISCIII*. We actively participate in research projects in collaboration with the CNIO and other Groups and are involved in a range of other extramural activities.

Main Objectives

- Supply tumour samples and offer related ethical advice to intramural and extramural research Groups, including cooperative Groups and clinical trials
- Promote collaborative groups in close connection with CNIO and clinical investigators and provide documentation and sample-oriented support to the Molecular Diagnostics Service
- Co-ordinate the Spanish National Tumour Bank Network, including nation-wide promotion of high quality tumour banks, sample collection protocols and agreements with local tumour banks and regional networks
- Co-ordinate the Spanish National Hospital-based Biobanks Network (ISCIII) and promote International Tumour Bank Networks and a harmonised approach to biobanking


Manuel M. Morente *Unit Head*

Manuel M. Morente was born in Madrid in 1954, received his MD degree from the *Universidad Autónoma de Madrid* in 1979 and his PhD from the *Universidad de Alcalá de Henares*, Madrid, in 1998.

Specialised in Pathology in 1984, he spent fifteen years working as both a Clinical Pathologist at the *Hospital General Universitario de Guadalajara*, Spain, and Associate Professor at the *Universidad de Alcalá de Henares*. He has been appointed as Head of the CNIO Tumour Bank Unit since the year 2000.

Aside from directing the CNIO's Tumour Bank Unit and acting as the main promoter and coordinator of the Spanish National Tumour Bank Network, a pioneer design in its field, Morente strives to promote other biobanks and networks throughout Europe and Latin America. He also collaborates in research projects surrounding the molecular profiling of cancer and clinical implications.

He actively participates in national and international Groups and societies involved in biobanking such as the International Society of Biological and Environmental Repositories (ISBER), for which he was appointed as Councillor from 2005 to 2008, and currently serves as member on several of its committees by invitation: the Marble Arch International Working Group for Biorepositories, Biobanking and Biomolecular Resources Research Infrastructure (BBMRI), the European Human Frozen Tumour Tissue Bank (Tubafrost), and the *Red Temática de Biobancos Hospitalarios* (ISCIII) and Tumour Bank Programme of the *Red Temática de Centros de Cáncer* (RTICC) for both of which he is the current coordinator.



Highlights

Technical implementations: the Tumour Bank Unit is currently implementing new standards in biobanking in accordance with the new Spanish legal framework for the use of human tissue samples in research, the OECD Best Practices Guidelines, ISBER Best Practices Guidelines (2nd edition, ISBER, 2008) and the IARC/WHO Common Minimum Technical Standards and Protocols for Biological Resource Centres dedicated to Cancer Research (IARC, 2007). These guidelines are included within the development of a global and institutional quality management system according to ISO normatives 15189 and 9001:2000. The Central Office of the CNIO's Tumour Bank Network has been awarded with the ISO-9001:2000 Quality Certification since 2003 (renewed in 2007).

Service Activities: as a biological resource centre, we have supported 168 requests of samples corresponding to 80 research projects throughout 2009, most of which belong to multicentre cooperative groups. The median impact factor (referred to 2008 values) of the 16 supported published projects in 2009 was 5.4



Technicians: M. Jesús Artiga, Laura Cereceda, Javier Gómez-Serranillos.

We have also provided samples and/or documental support for the CNIO's Molecular Diagnostic Unit (2,062 cases) and the familiar cancer activities of the CNIO's Human Cancer Genetics Programme (101 cases), and directly participated in 18 collaborative projects including 9 clinical trials.

The Tumour Bank Unit actively collaborates with the *Instituto de Salud Carlos III* in the development of a new legal framework for biobanking, the promotion of the upcoming *Red Temática de Biobancos Hospitalarios* which is coordinated by us, and the prototype activity of the BBMRI.

With regards to teaching, we have also promoted and/or participated in several courses and meetings, collaborated in training activities for undergraduates specialised in health documentation, and acted in an advisory capacity for emerging biobanks in Europe and Latin America.




Figure: Biobank processes

Publications

Molina-Privado I, et al. (2009). *E2F1* expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. *Cancer Res* 69, 4052-4058.

Sánchez-Espiridión B, et al. (2009). A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. *Clin Cancer Res* 15, 1367-1375.

Hewitt R, et al. (2009). Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable? *Cancer* 115, 4-9.

Aggarwal M, et al. (2009). Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. *Leuk Lymphoma* 50, 1699-1708.

Morente MM, Cereceda L, Artiga MJ (2009). Quality in tumor samples: a limiting step in cancer research. *Clin Transl Oncol* 11, 13-16.

Awards and Recognition

Member, Spanish National Institute of Health Expert Group for the Legal Framework in Biobanking

Member, Ethics Committee of the Spanish National Institute of Health

Coordinator, Spanish National Hospital-based Biobanks Network (ISCIII)